LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Disorders of Protein Synthesis
- 1st Edition, Volume 132 - September 7, 2022
- Editor: Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 7 8 0 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 7 8 1 - 2
Disorders of Protein Synthesis, Volume 132 in the Advances in Protein Chemistry and Structural Biology series, highlights new advances in the field, with this new volume presen… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteDisorders of Protein Synthesis, Volume 132 in the Advances in Protein Chemistry and Structural Biology series, highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Protein Chemistry and Structural Biology series
- Includes the latest information on disorders of protein synthesis
Researchers and students
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: Translation termination codons in protein synthesis and disease
- Abstract
- 1: Ribosome fidelity and translation termination
- 2: Nonsense mutations and the mRNA quality control
- 3: Ribosome readthrough
- 4: Readthrough induction as a therapeutic approach for PTC suppression
- 5: Conclusions
- Author contributions
- Funding
- Conflicts of interest
- References
- Chapter Two: The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders
- Abstract
- 1: Introduction
- 2: Proteostasis: The balance between synthesis, folding and degradation
- 3: The proteostasis network in the brain
- References
- Chapter Three: Computational and structural investigation of Palmitoyl-Protein Thioesterase 1 (PPT1) protein causing Neuronal Ceroid Lipofuscinoses (NCL)
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results
- 4: Discussion
- 5: Conclusion
- Acknowledgment
- Role of funding source
- Author contributions
- Conflict of interest
- References
- Chapter Four: Translation initiation and its relationship with metabolic mechanisms in cancer development, progression and chemoresistance
- Abstract
- 1: Introduction
- 2: Translation initiation and its regulation
- 3: The impact of translation initiation in cancer
- 4: Obesity and cancer
- 5: Final considerations
- Acknowledgments
- References
- Chapter Five: Cytoplasmic fatty acid-binding proteins in metabolic diseases and cancers
- Abstract
- 1: Introduction
- 2: FABPs: Their types, tissue distribution, and their putative function
- 3: FABPs in metabolic diseases
- 4: FABPs in various cancers
- 5: Conclusions
- Acknowledgments
- Declarations
- References
- Chapter Six: Protein expression in exocrine pancreatic diseases. Focus on VMP1 mediated autophagy
- Abstract
- 1: Introduction
- 2: The exocrine pancreas
- 3: The pancreatic acinar cell
- 4: The pancreatic proteins
- 5: Autophagy
- 6: VMP1 and pancreatitis
- 7: VMP1 and pancreatic cancer
- 8: VMP1 and cancer-related drug resistance
- 9: Conclusions
- References
- Further reading
- Chapter Seven: Deciphering the effect of mutations in MMAA protein causing methylmalonic acidemia—A computational approach
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results
- 4: Discussion
- 5: Conclusion
- Acknowledgments
- Author contributions
- Role of funding source
- References
- Chapter Eight: Intrinsically disordered proteins in viral pathogenesis and infections
- Abstract
- 1: Introduction
- 2: Intrinsically disordered proteins (IDPs)
- 3: Techniques involved in the prediction of IDPs
- 4: Disordered proteins regions in viral proteomes
- 5: IDPs in diseases
- 6: Roles of IDPs in protein interaction and PPI networks
- 7: Involvement of IDPs in the pathogen-host mediated regulation of cell cycle
- 8: Intrinsically disordered proteins in a SARS-CoV-2
- 9: Molecular mechanisms of drugs targeting ordered proteins
- 10: Lipid-binding activity of IDPs
- 11: Future prospectus
- Acknowledgment
- References
- Chapter Nine: Interaction between Sars-CoV-2 structural proteins and host cellular receptors: From basic mechanisms to clinical perspectives
- Abstract
- 1: Genome, proteins and life cycle of Sars-CoV-2
- 2: Key proteins of Sars-CoV-2
- 3: Lifecycle of Sars-CoV-2
- 4: Molecular mechanisms underlying Sars-CoV-2 induced pathological conditions
- 5: Sars-CoV-2 induced pathological conditions via mediation of ACE2
- 6: Conclusions
- 7: Future perspective
- Acknowledgments
- References
- No. of pages: 290
- Language: English
- Edition: 1
- Volume: 132
- Published: September 7, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323997805
- eBook ISBN: 9780323997812
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Disorders of Protein Synthesis on ScienceDirect